ATE352619T1 - Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten - Google Patents

Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten

Info

Publication number
ATE352619T1
ATE352619T1 AT99904660T AT99904660T ATE352619T1 AT E352619 T1 ATE352619 T1 AT E352619T1 AT 99904660 T AT99904660 T AT 99904660T AT 99904660 T AT99904660 T AT 99904660T AT E352619 T1 ATE352619 T1 AT E352619T1
Authority
AT
Austria
Prior art keywords
vertebrates
immunological compositions
modulating myostatin
myostatin
modulating
Prior art date
Application number
AT99904660T
Other languages
English (en)
Inventor
Christopher A Barker
Mohamad Morsey
Original Assignee
Metamorphix International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metamorphix International Inc filed Critical Metamorphix International Inc
Application granted granted Critical
Publication of ATE352619T1 publication Critical patent/ATE352619T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99904660T 1998-02-19 1999-02-19 Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten ATE352619T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7521398P 1998-02-19 1998-02-19

Publications (1)

Publication Number Publication Date
ATE352619T1 true ATE352619T1 (de) 2007-02-15

Family

ID=22124285

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06026306T ATE419353T1 (de) 1998-02-19 1999-02-19 Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten
AT99904660T ATE352619T1 (de) 1998-02-19 1999-02-19 Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06026306T ATE419353T1 (de) 1998-02-19 1999-02-19 Immunologische zusammensetzungen zur modulierung von myostatin in vertebraten

Country Status (18)

Country Link
US (2) US6369201B1 (de)
EP (3) EP2018871B1 (de)
JP (1) JP2002504326A (de)
KR (1) KR20010041111A (de)
AR (1) AR019818A1 (de)
AT (2) ATE419353T1 (de)
AU (1) AU765014B2 (de)
BR (1) BR9907995A (de)
CA (2) CA2687533C (de)
CY (2) CY1108074T1 (de)
DE (2) DE69940230D1 (de)
DK (2) DK1770162T3 (de)
ES (3) ES2280115T3 (de)
IL (1) IL137831A0 (de)
NZ (1) NZ506911A (de)
PT (2) PT1056845E (de)
WO (1) WO1999042573A1 (de)
ZA (1) ZA991369B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7566768B1 (en) * 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
JP2003517580A (ja) * 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
EE200200025A (et) * 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
US6617440B1 (en) 1999-07-30 2003-09-09 Pfizer, Inc. Myostatin regulatory region, nucleotide sequence determination and methods for its use
EP1593689A3 (de) * 2000-01-18 2006-04-05 Ovita Limited Myostatin und dessen Mimetika
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL374966A1 (en) * 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
BR0307907A2 (pt) * 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
AU2003267246A1 (en) * 2002-09-16 2004-04-30 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2003301195B2 (en) * 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005066204A2 (en) * 2003-12-31 2005-07-21 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
MX2007000976A (es) * 2004-08-12 2007-04-10 Wyeth Corp Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
CA2582940A1 (en) * 2004-09-30 2006-04-06 Orico Limited Myostatin isoform
MX2007008132A (es) * 2004-12-30 2007-07-20 Schering Plough Ltd Vacuna para aumentar el crecimiento basada en epitopes neutralizantes.
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP1864139A2 (de) * 2005-03-23 2007-12-12 Wyeth Nachweis einer immunreaktion auf gdf-8-modulierende wirkstoffe
US20070149458A1 (en) * 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
BRPI0715072A2 (pt) * 2006-08-03 2013-06-25 Orico Ltd antagonistas de miostatina
AU2013231037B2 (en) * 2006-08-03 2016-05-12 Myostin Therapeutics Pty Ltd Myostatin antagonists
HRP20130320T1 (en) 2006-09-05 2013-05-31 Eli Lilly And Company Anti-myostatin antibodies
AU2008285289A1 (en) 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
EP4678239A3 (de) 2012-08-01 2026-04-08 Ikaika Therapeutics, Inc. Abschwächung von gewebeschäden und fibrose über latentes transformierendes wachstumsfaktor-beta-bindendes protein (ltbp4)
CN104391628B (zh) * 2014-04-02 2018-02-23 贵阳朗玛信息技术股份有限公司 进程切换方法及装置
EP2960653A1 (de) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Diagnosekit und Verfahren zur Identifizierung der Manipulation der Muskelmasse bei einem Haustier
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
WO2020179571A1 (ja) * 2019-03-01 2020-09-10 神戸天然物化学株式会社 ミオスタチンスプライスバリアント由来タンパク質によるミオスタチンシグナル阻害とその利用
WO2025192635A1 (ja) * 2024-03-12 2025-09-18 リージョナルフィッシュ株式会社 魚類の肉質を改善する方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1605763A (en) 1926-11-02 Garment retainer
US2754818A (en) 1950-06-24 1956-07-17 Scherer Corp R P Hypo jet injector
US3330276A (en) 1963-10-07 1967-07-11 Scherer Corp R P Hypodermic jet injector
US3788315A (en) 1971-04-20 1974-01-29 S Laurens Disposable cutaneous transjector
US3853125A (en) 1971-10-05 1974-12-10 W Clark Disposable needleless injector
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4310550A (en) 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
JPS5873993U (ja) 1981-11-12 1983-05-19 三菱電機株式会社 ２気筒回転式圧縮機
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4518385A (en) 1983-06-13 1985-05-21 Preci-Tech Ltd. Disposable syringe for needleless injector
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5055400A (en) 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US4957739A (en) 1987-08-13 1990-09-18 Board Of Regents, The University Of Texas System Pharmaceutical compositions of a 105 kD P. Haemolytica derived antigen useful for treatment of Shipping Fever
US5151267A (en) 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
US5062830A (en) 1990-04-04 1991-11-05 Derata Corporation Dry disposable nozzle assembly for medical jet injector
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
DE69534468T2 (de) 1994-07-08 2006-07-13 The Johns Hopkins University School Of Medicine Wachstums-differenzierungsfaktor-11
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
WO1999002667A1 (en) 1997-07-14 1999-01-21 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
WO1999024618A1 (en) 1997-11-10 1999-05-20 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
WO1999040181A1 (en) 1998-02-05 1999-08-12 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
EE200200025A (et) 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto

Also Published As

Publication number Publication date
EP1056845A1 (de) 2000-12-06
ES2527410T3 (es) 2015-01-23
EP1770162B1 (de) 2008-12-31
US20030065137A1 (en) 2003-04-03
EP1770162A1 (de) 2007-04-04
CA2323607C (en) 2009-12-22
JP2002504326A (ja) 2002-02-12
AU765014B2 (en) 2003-09-04
AR019818A1 (es) 2002-03-20
DE69934970D1 (de) 2007-03-15
ZA991369B (en) 1999-08-20
US6369201B1 (en) 2002-04-09
DE69940230D1 (de) 2009-02-12
ES2318654T3 (es) 2009-05-01
CA2687533A1 (en) 1999-08-26
CY1108074T1 (el) 2014-02-12
AU2507399A (en) 1999-09-06
CY1108889T1 (el) 2014-07-02
NZ506911A (en) 2003-09-26
DK1770162T3 (da) 2009-04-14
ATE419353T1 (de) 2009-01-15
PT1770162E (pt) 2009-03-24
PT1056845E (pt) 2007-04-30
DE69934970T2 (de) 2007-10-25
BR9907995A (pt) 2001-05-15
EP2018871B1 (de) 2014-10-08
KR20010041111A (ko) 2001-05-15
DK1056845T3 (da) 2007-05-29
EP1056845B1 (de) 2007-01-24
CA2323607A1 (en) 1999-08-26
ES2280115T3 (es) 2007-09-01
WO1999042573A1 (en) 1999-08-26
IL137831A0 (en) 2001-10-31
EP2018871A1 (de) 2009-01-28
CA2687533C (en) 2016-02-02

Similar Documents

Publication Publication Date Title
DE69940230D1 (de) Immunologische Zusammensetzungen zur Modulierung von Myostatin in Vertebraten
DE69819033D1 (de) Zusammensetzungen zum kleben von fluorkunststoffen
ID28965A (id) Azabisikloalkana sebagai modulator ccr5
DE60041430D1 (de) Zusammensetzung zur Entfernung von Photoresist
DE69734090D1 (de) Web-Seiten Schnittstelle zur Angabe von Telefonie-Spezifikationen
ID26186A (id) Komposisi sampo
DE69934918D1 (de) Brennstoffzusammensetzung
ID22931A (id) Komposisi-komposisi herbisidal
ID26926A (id) Komposisi shampo pembentuk mode
ID16251A (id) Komposisi-komposisi pembasmi kuman
DE69733395D1 (de) Motorzusammensetzung
DE69903545D1 (de) Ölzusammensetzungen
ATE261429T1 (de) Neue 3-aryl-2-hydroxypropionsäure-derivate iii
DE69927758D1 (de) Imidosilan-Zusammensetzungen
DE69908507D1 (de) Zusammensetzung zur Bekämpfung von schädlichen Arthropoden
DE69936208D1 (de) Modifiziermittel enthaltende zusammensetzung
DE59911148D1 (de) Propoxilat enthaltende kraftstoffzusammensetzungen
DE59806510D1 (de) Verfahren zur Kennzeichnung von Gehäusen
FR2782522B1 (fr) Composition hydrofuge
DE69938619D1 (de) Weisse Tonerzusammensetzung
DE69524995D1 (de) Schaltung zur Modulation der Abtastgeschwindigkeit
EP1000916A4 (de) Wirkungverstärkende zusammensetzung für aufblasvorrichtung
DE69804573D1 (de) Organopolysiloxan-Zusammensetzungen
FI990228L (fi) Paperinvalmistuksen lisäainekoostumus
DE69712523D1 (de) Flüssige kohlenwasserstoffzusammensetzungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1056845

Country of ref document: EP